This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.
Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jadersten M, Jansson M, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015;126:233–41.
Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478:64–9.
Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl J Med. 2011;365:1384–95.
Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood 2020;136:157–70.
Komrokji RS, Volpe VO, Chan O, Al Ali NH, Swoboda DM, Kuykendall AT, et al. Validation of the International Working Group Proposal for SF3B1 mutant myelodysplastic syndromes. Blood. 2021;138:989–92.
Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl J Med. 2011;364:2496–506.
Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014;28:241–7.
Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, et al. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia 2019;33:1747–58.
Sallman DA. The Problem of TP53-Mutant MDS/AML. Clin Lymphoma Myeloma Leuk. 2020;20(Suppl 1):S65–S6.
Mufti GJ, Bennett JM, Goasguen J, Bain BJ, Baumann I, Brunning R, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 2008;93:1712–7.
Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, et al. Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J Clin Oncol. 2021;39:1584–94.
Sallman DA, Al Malki M, Asch AS, Lee DJ, Kambhampati S, Donnellan WB, et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results. J Clin Oncol. 2020;38(15_suppl):7507.
Hunter AM, Sallman DA. Targeting TP53 mutations in myelodysplastic syndromes. Hematol Oncol Clin North Am. 2020;34:421–40.
Sallman D, Asch AS, Kambhampati S, Malki M, Zeidner JF, Donnellan W, et al. The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in AML patients: phase 1b results. Blood. 2019;134:569.
Author information
Authors and Affiliations
Contributions
DMS and DAS designed the study, performed statistical analysis, and wrote the manuscript. RKS, AMB, TC, OC, NAA, GMB, QJG, AG, AMH, JL, ATK, CT, KS, JEL, EP, MH, JS, GGM, and RSK contributed patients and/or collected data and/or participated in the interpretation of results. All authors approved final manuscript.
Corresponding author
Ethics declarations
Competing interests
DMS, RKS, TC, OC, NAA, GMB, QJG, AG, AMH, JL, JS, and GGM declare no conflict of interest. AMB has done consulting for Novartis, BMS, Agios, Acceleron, and Takeda. ATK has done consulting for Abbvie, Blueprint, Celgene/BMS, Incyte, Novartis, PharmaEssentia, Protagonist, CTI Biopharma and has been part of a speaker’s bureau for Blueprint and Novartis. He receives research support from Sierra, Protagonist, and Prelude. CT is on advisory boards for Abbvie, BMS, Celgene, Daiichi Sankyo, Pfizer, and Novartis and has been part of a speaker’s bureau for Astellas, BMS, and Jazz. KS is on advisory committees for Arog, BMS, Gilead and Novartis. She has received research funding from Incyte and has received Honoraria from Stemline and Astellas. JEL has done consulting for AbbVie, Agios, Astella, Daiichi Sankyo, ElevateBio, Jazz, and Takeda and received Honoria from Agios. EP obtains research funding from Incyte, Kura Oncology, and BMS and has received Honoraria from Taiho. MH has done consulting and received honoraria from Adaptive Biotechnology, Stemline, Amgen, Seattle Genetics, BMS, Boston Biomedical, Decibio, Wells Fargo, Pivot and Blueprint Medicine. GGM RSK has been part of a speaker’s bureau for Jazz and BMS and received honoraria from JAZZ, BMS, Abbvie, Acceleron, Novartis, and Geron. DAS has received research funding from Aprea and Jazz, done consulting for AbbVie, Agios, Aprea, BMS, Incyte, Intellia, Kite, Magenta, Novartis, Shattuck Labs, and Takeda and part of a speaker’s bureau for BMS, Incyte. None of these relationships were related to the development of this manuscript.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Swoboda, D.M., Kanagal-Shamanna, R., Brunner, A.M. et al. Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts. Leukemia 36, 1189–1192 (2022). https://doi.org/10.1038/s41375-021-01486-w
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-021-01486-w